V
Vivebiotech
A GMP contract development and manufacturing organization (CDMO) specialized in Lentiviral vectors
About Vivebiotech
VIVEbiotech is a Contract Development and Manufacturing Organization (CDMO) that specializes in the production of lentiviral vectors, a critical component in gene and cell therapies. The company provides its services to the biopharmaceutical industry, assisting clients from the early stages of research and preclinical development through to GMP-compliant manufacturing for clinical and commercial use.
Operating under both European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA) standards, VIVEbiotech positions itself as a dedicated partner in the advanced therapies field. Its business model is centered on providing comprehensive manufacturing services and expertise in lentiviral vector technology. The company generates revenue by contracting its development and manufacturing capabilities to biotech and pharmaceutical companies that are developing cell and gene therapies.
Source: Dealroom company dataAt a glance
- Founded
- 2015
- Headquarters
- San Sebastián, Spain
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Inveready
Easo Ventures
Series B and later2 investors entered at this stage
CDTI Innvierte
Ampersand Capital Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Vivebiotech on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Vivebiotech on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.